Education
About Us
Working with TipRanks
Follow Us
Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
ACRV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.49 - $11.90
Previous CloseN/A
Volume1.72K
Average Volume (3M)64.28K
Market Cap
$165.33M
Enterprise Value$83.30M
Total Cash (Recent Filing)$99.60M
Total Debt (Recent Filing)$5.63M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Mar 26, 2025EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.70
Shares Outstanding31,136,295
10 Day Avg. Volume52,185
30 Day Avg. Volume64,282
Standard Deviation0.26
R-Squared0.01
Alpha-0.00907
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1233.83
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-155.40
Enterprise Value/Ebitda-0.98
Forecast
1Y Price Target
$17.50Price Target Upside229.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentAcrivon's recent pipeline update highlights the completion of the first dose-escalation cohort in a Phase 1 trial for their dual inhibitor ACR-2316, moving clinical development ahead of schedule.
Financial StabilityAcrivon's cash position is strong with approximately $202.8 million in cash and equivalents, projecting a cash runway into the second half of 2026.
Bears Say
Clinical RisksClinical risks include the potential for slow accrual of patients, which could impact trial progress and outcomes.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACRV FAQ
What was Acrivon Therapeutics, Inc.’s price range in the past 12 months?
Acrivon Therapeutics, Inc. lowest stock price was $4.49 and its highest was $11.90 in the past 12 months.
What is Acrivon Therapeutics, Inc.’s market cap?
Acrivon Therapeutics, Inc.’s market cap is $165.33M.
When is Acrivon Therapeutics, Inc.’s upcoming earnings report date?
Acrivon Therapeutics, Inc.’s upcoming earnings report date is Mar 26, 2025 which is in 22 days.
How were Acrivon Therapeutics, Inc.’s earnings last quarter?
Acrivon Therapeutics, Inc. released its earnings results on Nov 13, 2024. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.578 by -$0.012.
Is Acrivon Therapeutics, Inc. overvalued?
According to Wall Street analysts Acrivon Therapeutics, Inc.’s price is currently Undervalued.
Does Acrivon Therapeutics, Inc. pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
What is Acrivon Therapeutics, Inc.’s EPS estimate?
Acrivon Therapeutics, Inc.’s EPS estimate is -0.66.
How many shares outstanding does Acrivon Therapeutics, Inc. have?
Acrivon Therapeutics, Inc. has 31,136,295 shares outstanding.
What happened to Acrivon Therapeutics, Inc.’s price movement after its last earnings report?
Acrivon Therapeutics, Inc. reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.578. Following the earnings report the stock price went down -5.483%.
Which hedge fund is a major shareholder of Acrivon Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ACRV
---
Acrivon Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.50 (229.57% Upside)
$17.50 (229.57% Upside)
Blogger Sentiment
Bullish
ACRV Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.79%
12-Months-Change
Fundamentals
Return on Equity
-45.95%
Trailing 12-Months
Asset Growth
42.09%
Trailing 12-Months
Company Description
Acrivon Therapeutics, Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
---
ACRV Stock 12 Month Forecast
Average Price Target
$17.50
▲(229.57% Upside)
Technical Analysis
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Bluebird Bio
―
Blueprint Medicines
―
Best Analysts Covering ACRV
1 Year
1 Year Success Rate
2/8 ratings generated profit
1 Year Average Return
-12.84%
reiterated a buy rating 4 months ago
Copying Etzer Darout's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -12.84% per trade.
---